



You are entering a medical section of the Pfizer Landing Page. All materials here are presented for purposes of scientific exchange. They are NOT presented for any promotional purpose.

## Pfizer Oral Presentations

Oral presentations will be presented in Central European Summer Time (CEST).

### Proffered Paper session - Genitourinary tumors, prostate

Saturday, September 18

2:20 PM – 2:30 PM

#### Enzalutamide

LBA25

Overall survival (OS) from ARCHES: Final analysis of the phase 3, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC)\*

Armstrong AJ

Presentation is supported by Astellas and Pfizer.

[View Presentation](#)

### Proffered Paper session - Sars-CoV-2 and cancer

Tuesday, September 21

1:40 PM – 1:50 PM

#### COVID-19/Pan-Oncology

1558O

COVID vaccine in participants (ptcpts) with cancer: subgroup analysis of safety/efficacy from a global phase 3 randomized trial of the BNT162b2 (tozinameran) mRNA vaccine

Thomas SJ

[View Presentation](#)

### Mini Oral session - Breast cancer, metastatic

Saturday, September 18

5:50 PM – 5:55 PM

#### Palbociclib

228MO

PALOMA-4: Primary results from a phase 3 trial of palbociclib (PAL) + letrozole (LET) vs placebo (PBO) + LET in Asian postmenopausal women with estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced breast cancer (ABC)

Xu B

[View Presentation](#)

### Mini Oral session - Melanoma and other skin tumors

Monday, September 20

6:00 PM – 6:05 PM

#### Encorafenib/Binimetinib

1041MO

5-year update on COLUMBUS: a randomized phase 3 trial of encorafenib (enco) + binimetinib (bini) versus enco or vemurafenib (vem) in patients (pts) with BRAF V600-mutant melanoma

Dummer R

[View Presentation](#)

## Pfizer ePosters

ESMO ePosters will be accessible on demand starting Thursday, September 16, 2021, at 8:30 AM CEST.

#### Avelumab

665P

Role of prior nephrectomy for synchronous metastatic renal cell carcinoma (mRCC) on efficacy in patients treated with avelumab + axitinib (A + Ax) or sunitinib (S): results from JAVELIN Renal 101

Grimm MO

[View Presentation](#)

#### Avelumab

701P

Real-world (RW) treatment (Tx) patterns and clinical outcomes in patients (pts) with metastatic urothelial carcinoma (mUC) receiving first line (1L) Tx: results from IMPACT UC

Bilen MA

[View Presentation](#)

#### Avelumab

706P

Real-world study assessing physician rationale for initiating first-line (1L) immuno-oncology (IO) therapy for patients with advanced urothelial cancer (aUC)

Ajmera M

[View Presentation](#)

#### Avelumab

707P

Treatment pattern and overall survival among patients with locally advanced or metastatic urothelial carcinoma – results from a complete nationwide unselected real-world registry study in Denmark from 2010 to 2017

Jensen JB

[View Presentation](#)

#### Encorafenib/Binimetinib

1091TIP

STARBOARD: randomized phase 3 study of encorafenib (enco) + binimetinib (bini) + pembrolizumab (pembro) for first-line treatment of metastatic or unresectable locally advanced BRAF V600-mutant melanoma

Schadendorf D

[View Presentation](#)

#### Enzalutamide

609P

Treatment patterns and overall survival (OS) in metastatic castration-sensitive prostate cancer (mCSPC) from 2006 to 2019

Freedland SJ

[View Presentation](#)

#### Enzalutamide

616P

Real-world utilization of advanced therapies by site of metastasis and age among patients with metastatic castration-sensitive prostate cancer (mCSPC): a Medicare database analysis

George DJ

[View Presentation](#)

#### Lorlatinib

1196P

Pre-existing and acquired mechanisms of resistance to lorlatinib in previously treated patients (pts) with ALK+ advanced non-small cell lung cancer (NSCLC)

Solomon BJ

[View Presentation](#)

#### Lorlatinib

1197P

First-line lorlatinib versus crizotinib in ALK-positive NSCLC: Asian subgroup analysis of CROWN

Zhou Q\*\*; Kim HR\*\*

[View Presentation](#)

#### Lorlatinib

1199P

Dose modification for the management of CNS adverse events in the Phase 3 CROWN study of lorlatinib in non-small cell lung cancer (NSCLC)

Solomon BJ

[View Presentation](#)

#### Palbociclib

234P

Effect of palbociclib (PAL) + endocrine therapy (ET) on time to chemotherapy (TTC) across subgroups of patients (pts) with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC): post hoc analyses from PALOMA-2 (P2) and PALOMA-3 (P3)

Rugo HS

[View Presentation](#)

#### Palbociclib

236P

Real-world comparative effectiveness of palbociclib plus letrozole vs letrozole in older patients with metastatic breast cancer

Rugo HS

[View Presentation](#)

#### Palbociclib

246P

Palbociclib dose patterns in Swedish patients with metastatic breast cancer: Evidence from the SIRI study

Valachis A

[View Presentation](#)

#### Palbociclib

251P

First-line treatments and clinical outcomes for hormone receptor-positive, human epidermal growth factor 2-positive advanced or metastatic breast cancer: a systematic literature review

Chang R

[View Presentation](#)

#### Palbociclib

315P

Treatment patterns in Black and Indigenous people and people of color (BIPOC) receiving palbociclib for hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) in a real-world setting: POLARIS study results

Rocque GB

[View Presentation](#)

#### Relugolix

621P

Efficacy and safety of relugolix vs leuprolide (LEU) in men with advanced prostate cancer (APC): clinical subgroup analysis from the phase 3 HERO study

Saltzstein DR

[View Presentation](#)

#### Relugolix

622P

Geographical assessment of efficacy and safety of relugolix: a subgroup analysis from the randomized, phase 3 HERO study vs leuprolide (LEU) in men with advanced prostate cancer (APC)

Bossi A

[View Presentation](#)

#### Talazoparib

269P

Patient-reported outcomes (PRO) with talazoparib (TALA) vs physician's choice chemotherapy (PCT) in patients (pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm): Subgroup analysis of pts with and without TALA dose reductions vs PCT in the EMBRACA trial

Rugo HS

[View Presentation](#)

#### Talazoparib

272P

Outcomes of patients (pts) who had received prior platinum (PP) therapy in the phase 3 EMBRACA trial of talazoparib (TALA) vs physician's choice of chemotherapy (PCT) in patients with germline BRCA1/2 mutated (gBRCA1/2mut) advanced breast cancer (ABC)

Martin M

[View Presentation](#)

#### Talazoparib

273P

Talazoparib (TALA) for patients with germline BRCA1/2 mutated (gBRCA1/2mut) advanced breast cancer (ABC): characteristics of patients who experienced hematologic toxicity in the phase 3 EMBRACA trial

Hurvitz SA

[View Presentation](#)

#### Talazoparib

580P

TALAPRO-1: Talazoparib (TALA) monotherapy in metastatic castration-resistant prostate cancer (mCRPC) with DNA damage response alterations (DDRM)—exploration of non-DDRM mutational landscape and potential associations with antitumor activity

Mehra N

[View Presentation](#)

#### Talazoparib

581P

Patient (pt) reported pain in men with metastatic castration resistant prostate cancer (mCRPC) receiving talazoparib (TALA): TALAPRO-1

Saad F

[View Presentation](#)

#### Talazoparib

645TIP

TALAPRO-3: a phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) vs placebo plus ENZA in patients (Pts) with DDR gene mutated metastatic castration-sensitive prostate cancer (mCSPC)

Agarwal N

[View Presentation](#)

\*Accepted as a late-breaking abstract.

\*\*Co-authorship.